Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for ...

In the case of tarlatamab, the molecule binds to CD3 receptors on T cells and DLL3 on SCLC cells with the aim of stimulating the immune system to destroy the tumour. It’s a well-established ...

Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors ...

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...

The ADRIATIC study included 730 patients with stages I-III LS-SCLC who had not progressed after concurrent chemoradiotherapy. Participants were randomized to receive durvalumab, placebo ...

AstraZeneca’s IMFINZI TM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...